SineuGene Therapeutics is a biopharmaceutical company focusing on gene therapy for brain disorders. Founded in late 2021, the company builds on more than a decade of research on neuroscience by JiaLab at Tsinghua University's School of Medicine.
SineuGene has established innovative animal disease models, such as fruit flies, mice, and Bama pigs, to better understand the characteristics of neurological diseases and identify viable targets for drug development. The company has also developed a platforam for screening central nervous system-specific adeno-associated viruses (AAVs) with high targeting specificity, delivery efficiency, and low immunogenicity. We have also established a platform for developing central nervous system small nucleic acid drugs, covering target screening, sequence design optimization, nucleic acid synthesis, chemical modifications, and delivery technology development. With its expertise in gene expression and editing technology, and nucleic acid-mediated gene expression regulation, SineuGene is committed to developing effective treatments for neurological diseases such as ALS, stroke, Parkinson's disease, Alzheimer's disease, Huntington's chorea, and Autism spectrum disorder.
SineuGene's three co-founders, Professor Jia Yichang (Founder), Dr. Peng Lin (CEO), and Dr. Guo Wei (CSO), all have backgrounds in Tsinghua University, forming a complementary triangle between academia, industry, and research. Over 70% of team members have master's or doctoral degrees from renowned domestic and foreign institutions, such as Tsinghua University, Peking University, the Chinese Academy of Sciences, the Beijing Institute of Life Sciences, and Johns Hopkins University, with extensive experience in drug development, clinical operations, and basic research. To support drug development through the entire process, the company has built a modular platform covering target discovery, conceptual verification, screening and optimization, preclinical studies, CMC, regulatory submission, and medical and clinical operations.
SineuGene's vision is to provide effective and safe gene therapy solutions for patients worldwide suffering from neurological diseases.
Yichang Jia, Ph.D.
Co-founder and the Chairman of Scientific Advisory Board of SineuGene
Dr. Yichang Jia is the Tenured Professor in School of Medicine, Tsinghua University. He is also a Principal Investigator of Center for Life Sciences (CLS), IDG/McGovern Institute for Brain Research at Tsinghua University, and Tsinghua Laboratory of Brain and Intelligence. Dr. Jia got his Ph.D. in Institute of Neuroscience, Chinese Academy of Sciences, and his postdoctoral training in The Jackson Laboratory, Maine. He has employed mouse genetics to study the disease mechanism underlying neurodegenerative diseases since his postdoctoral training.
Lin Peng, Ph.D.
Co-founder and Chief Executive Officer (CEO) of SineuGene.
Dr. Peng got his Bachelor and Master in the College of Life Sciences, Beijing Normal University. He got his Public Policy and Management Discipline Ph.D. degree in the Institute of Education (Mentor, Dr. Jian Lin), Tsinghua University. He was a visiting scholar in the Global Engineering Education Collaboratory (GEEC), College of Engineering, Purdue University (West Lafayette, IN). Dr. Peng worked at the School of Life Sciences at Tsinghua and Westlake Institute for Advanced Study (WIAS). In WIAS, he worked for Dr. Yigong Shi as Dean Assistant to help on setting up of Westlake University. Before joining SineuGene, he was the CEO of Tianyin Health Development Co., Ltd, Nanjing, Jiangsu, China. Dr. Peng's biological background, business management skills, entrepreneurship ensure his leadership at SineuGene.
Wei Guo, Ph.D.
Co-founder and Chief Scientific Officer (CSO) of SineuGene.
Dr. Wei Guogothis bachelor in biochemistry, Nanjing University, China and his Ph.D. in Institute of Neuroscience,Chinese Academy of Sciences, Shanghai. After his postdoc training with Dr. Bai Lu in School of Life Sciences, Tsinghua University, he worked as a full-time employee in the neurodegenerative disease department, GlaxoSmithKline (GSK).Prior to co-founding SineuGene, he was an Associate Professor at School of Pharmaceutical Sciences, Tsinghua University, and helped to managea research team with more than30 people. He has studied neurodegenerative diseases and has been involved in the innovative drug development for the devastating diseases for more than 20 years. He has published his cutting-edge research inCell Res.,Nat. Comm., and others as a corresponding author. He also holds a number of international PCT patents. He had also been involved in the establishments of several innovative pharmaceutical companies and helped build R&D pipelines. Dr. Guo’s leadership and enriched experiences in basic research and translational medicine ensure his successful management of R&D at SineuGene.
Scientific Advisory Committee
PI at School of Medicine Tsinghua University McGovern Brain Institute Researcher
Academician of Chinese Academy of Sciences
Vice president of JD
Professor at School of Medicine, Tsinghua University
Chairman of Cyagen (Guangzhou) Biotechnology Co., Ltd
Chairman of PackGene (Guangzhou) Biotechnology Co., Ltdr